JSC
VYNT

Jackson Square Capital’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Jackson Square Capital’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,078
Closed -$17K – 141
2022
Q3 		$17K Hold
6,078
– – 0.01% 122
2022
Q2 		$28K Hold
6,078
– – 0.01% 138
2022
Q1 		$43K Hold
6,078
– – 0.01% 178
2021
Q4 		$41K Hold
6,078
– – 0.01% 187
2021
Q3 		$71K Hold
6,078
– – 0.02% 173
2021
Q2 		$114K Buy
+6,078
New +$113K 0.04% 177

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Jackson Square Capital's VYNT Position: Q4 2022 in Review

Jackson Square Capital sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2022, closing a stake of 6,078 shares — an estimated $17K sold.

Jackson Square Capital first reported a position in VYNT in Q2 2021 and held it in 6 quarters. The position peaked at $114K in Q2 2021. 17 funds tracked by Wall St. Rank hold VYNT as of Q4 2022.

  • Jackson Square Capital reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Jackson Square Capital sold 6,078 Vyant Bio, Inc. Common Stock shares in Q4 2022, an estimated $17K.
  • Jackson Square Capital first reported a position in Vyant Bio, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
  • Jackson Square Capital's Vyant Bio, Inc. Common Stock position peaked at $114K in Q2 2021.
  • 17 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2022.

Based on Jackson Square Capital's 13F filing for Q4 2022, filed 23 Jan 2023.